June 2009 Volume 27 Number 6, pp 487 - 578
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=47&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=28&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=36&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=6&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
qPCR - Ready, Set, Done!
Easily and quickly quantify genes in cellular pathways and gene
families.
RealTime ready Focus Panels are pre-plated with gene-specific primers,
probes, controls and reference genes.
Just add master mix and sample cDNA. More RealTime ready information
is available here http://links.ealert.nature.com/ctt?kn=117&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Play your part - Help bring new multiple sclerosis treatments to market.
$3 million in funding available now for innovative research and commercial
development proposals.
Who can apply?
- Academic investigators
- Seed and early stage companies
To submit your proposal visit:
http://links.ealert.nature.com/ctt?kn=7&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Fast Forward(SM) Speeding treatments to people with MS
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
SciBX: Science - Business eXchange from NPG and BioCentury
Joining the scientific acumen of NPG and the business intelligence of BioCentury to evaluate new developments in life science and technology that have commercial and investment potential for the pharmaceutical and biotechnology industries.
Visit http://links.ealert.nature.com/ctt?kn=3&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0 to reserve your copy of this new weekly groundbreaking publication today.
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Novel strategies for HIV therapy
www.nature.com/scibx/journal/v2/n16/full/scibx.2009.645.html
Two research teams are proposing the use of known compounds-the mild surfactant glycerol monolaurate and a protein called griffithsin that could be scaled up in tobacco-be used to block distinct steps in the early stages of HIV infection. Both teams already have commercial links but what challenges lay ahead?
Find out more by reading the first in-depth analysis of the scientific and commercial potential of the work in SciBX: Science-Business eXchange.
http://links.ealert.nature.com/ctt?kn=101&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
The genome-assisted barnyard p487
In contrast to the slow translation of human genome information into medicine, animal genomics is likely to have a rapid and tangible impact on agriculture.
doi:10.1038/nbt0609-487
http://links.ealert.nature.com/ctt?kn=91&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
----------------------
NEWS
----------------------
Flu vaccine makers upgrade technology - and pray for time pp489 - 491
Cormac Sheridan
doi:10.1038/nbt0609-489
http://links.ealert.nature.com/ctt?kn=24&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Taiwan builds biotech runway p490
Susan Aldridge
doi:10.1038/nbt0609-490
http://links.ealert.nature.com/ctt?kn=138&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Profiting from pandemics p491
Brady Huggett
doi:10.1038/nbt0609-491
http://links.ealert.nature.com/ctt?kn=121&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Boardroom tensions rise as investors push for liquidation pp492 - 493
Brian Orelli
doi:10.1038/nbt0609-492
http://links.ealert.nature.com/ctt?kn=40&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Still strapped for cash p493
Brady Huggett
doi:10.1038/nbt0609-493
http://links.ealert.nature.com/ctt?kn=89&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Mixed news for Avastin p494
George S Mack
doi:10.1038/nbt0609-494a
http://links.ealert.nature.com/ctt?kn=56&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Ariad's NF[kappa]B patent claims shot down on appeal pp494 - 495
Ken Garber
doi:10.1038/nbt0609-494b
http://links.ealert.nature.com/ctt?kn=132&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
TNF-blocker triple approval p495
James Netterwald
doi:10.1038/nbt0609-495
http://links.ealert.nature.com/ctt?kn=18&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Phase zero launch p496
Emma Dorey
doi:10.1038/nbt0609-496a
http://links.ealert.nature.com/ctt?kn=72&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Pig patent revolt p496
Anna Meldolesi
doi:10.1038/nbt0609-496b
http://links.ealert.nature.com/ctt?kn=112&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
US regulator wades into stem cell therapies for heart disease pp496 - 498
Randy Osborne
doi:10.1038/nbt0609-496c
http://links.ealert.nature.com/ctt?kn=122&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Genzyme takes Campath bet p498
Brady Huggett
doi:10.1038/nbt0609-498a
http://links.ealert.nature.com/ctt?kn=134&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
India's first true stem cell trials p498
Killugudi Jayaraman
doi:10.1038/nbt0609-498c
http://links.ealert.nature.com/ctt?kn=22&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
NEWS FEATURE
Vaccine market boosters pp499 - 501
Recent commercial success belies conventional wisdom that vaccines are a low-margin, moribund sector. But will the trend continue? Cormac Sheridan investigates.
Cormac Sheridan
doi:10.1038/nbt0609-499
http://links.ealert.nature.com/ctt?kn=21&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Can you hear me in the back?
With thousands of biotech companies out there, and just as many corporate presentations, here's how to differentiate your enterprise in an increasingly crowded marketplace.
Carin Canale
doi:10.1038/bioe.2009.4
http://links.ealert.nature.com/ctt?kn=74&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Pharma's role is not to bankroll biotech p504
Martin Mackay
doi:10.1038/nbt0609-504a
http://links.ealert.nature.com/ctt?kn=127&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Conflating MTAs and patents pp504 - 505
Kevin E Noonan
doi:10.1038/nbt0609-504b
http://links.ealert.nature.com/ctt?kn=123&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Reply to Conflating MTAs and patents p505
doi:10.1038/nbt0609-505
http://links.ealert.nature.com/ctt?kn=113&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
First GM trial in Belgium since 2002 p506
Rene Custers
doi:10.1038/nbt0609-506
http://links.ealert.nature.com/ctt?kn=33&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
A European perspective on immunogenicity evaluation pp507 - 508
Christian K Schneider, Marisa Papaluca and Pekka Kurki
doi:10.1038/nbt0609-507
http://links.ealert.nature.com/ctt?kn=42&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Reflect: augmented browsing for the life scientist pp508 - 510
Evangelos Pafilis et al.
doi:10.1038/nbt0609-508
http://links.ealert.nature.com/ctt?kn=71&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Extrapolating from sequence[mdash]the 2009 H1N1 'swine' influenza virus pp510 - 513
Venkataramanan Soundararajan et al.
doi:10.1038/nbt0609-510
http://links.ealert.nature.com/ctt?kn=60&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
COMMENTARY
Science communication reconsidered pp514 - 518
As new media proliferate and the public's trust and engagement in science are influenced by industry involvement in academic research, an interdisciplinary workshop provides some recommendations to enhance science communication.
Tania Bubela et al.
doi:10.1038/nbt0609-514
http://links.ealert.nature.com/ctt?kn=130&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Strangled at birth? Forest biotech and the Convention on Biological Diversity pp519 - 527
Against the Cartagena Protocol and widespread scientific support for a case-by-case approach to regulation, the Convention on Biological Diversity has become a platform for imposing broad restrictions on research and development of all types of transgenic trees.
Steven H. Strauss, Huimin Tan, Wout Boerjan and Roger Sedjo
doi:10.1038/nbt0609-519
http://links.ealert.nature.com/ctt?kn=131&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
----------------------
FEATURES
----------------------
Masters of their universe pp528 - 530
Nature Biotechnology talks to some of the leading characters behind the Genentech legend.
Randy Osborne and Laura DeFrancesco
doi:10.1038/nbt0609-528
http://links.ealert.nature.com/ctt?kn=109&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Wasting cash - the decline of the British biotech sector pp531 - 537
Undercapitalization and overgenerous boardroom compensation for management have been major contributors to the poor performance of UK biotech.
Graham Smith, Muhammad Safwan Akram, Keith Redpath and William Bains
doi:10.1038/nbt0609-531
http://links.ealert.nature.com/ctt?kn=35&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
PATENTS
A day late and a few million dollars short pp538 - 541
The pitfalls of seeking and obtaining a patent term extension.
Dianna Goldenson
doi:10.1038/nbt0609-538
http://links.ealert.nature.com/ctt?kn=57&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Recent patent applications in genomic assays p542
doi:10.1038/nbt0609-542
http://links.ealert.nature.com/ctt?kn=85&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Shining light on a new class of hydrogels pp543 - 544
Addition of a photodegradable group to the backbone of synthetic hydrogels enables real-time control of the material's chemical and physical properties.
Steven M Jay and W Mark Saltzman
doi:10.1038/nbt0609-543
http://links.ealert.nature.com/ctt?kn=75&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Cause and express pp544 - 545
Biological validation of a cadre of new obesity genes supports the power of studies that exploit 'expression quantitative trait loci'.
Leonid Kruglyak and John D Storey
doi:10.1038/nbt0609-544
http://links.ealert.nature.com/ctt?kn=23&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Structure of a multidrug transporter pp546 - 547
Crystal structures of a mammalian multidrug efflux pump bound to peptide inhibitors may reveal drug-binding sites.
Michael M Gottesman, Suresh V Ambudkar and Di Xia
doi:10.1038/nbt0609-546
http://links.ealert.nature.com/ctt?kn=83&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p548
doi:10.1038/nbt0609-548
http://links.ealert.nature.com/ctt?kn=110&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
BRIEF COMMUNICATION
Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture pp557 - 559
Forrester et al. adapt the biotin switch technique for studying reversible protein modification by nitric oxide, by using resin-assisted capture of S-nitrosothiols. This enables more sensitive detection of larger S-nitrosylated proteins and can be coupled with quantitative mass spectrometry to study the kinetics of denitrosylation.
Michael T Forrester et al.
doi:10.1038/nbt.1545
Abstract: http://links.ealert.nature.com/ctt?kn=82&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=44&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
ARTICLE
Genome sequence of the recombinant protein production host Pichia pastoris pp561 - 566
Pichia pastoris has been a workhorse of protein production for decades. De Schutter et al. present its genomic sequence, which will allow development of improved strains.
Kristof De Schutter et al.
doi:10.1038/nbt.1544
Abstract: http://links.ealert.nature.com/ctt?kn=99&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=17&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
LETTERS
Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein pp567 - 571
The delivery to primary cells is a major challenge in the application of siRNAs in biological research. Using a fusion protein consisting of a double-stranded RNA binding domain and a protein transduction domain, Eguchi et al. are able to transfect siRNAs into a wide variety of cells with very high efficiency without cytotoxicity.
Akiko Eguchi et al.
doi:10.1038/nbt.1541
Abstract: http://links.ealert.nature.com/ctt?kn=12&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=116&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
MicroRNA-mediated species-specific attenuation of influenza A virus pp572 - 576
Traditional methods for modifying viruses to produce live attenuated vaccines are being updated with molecularly targeted approaches. Perez et al. attenuate influenza A viruses by introducing miRNA target sites into the coding region of the viral genome.
Jasmine T Perez et al.
doi:10.1038/nbt.1542
Abstract: http://links.ealert.nature.com/ctt?kn=1&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=135&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
----------------------
CAREERS AND RECRUITMENT
----------------------
CAREERS AND RECRUITMENT
Career interrupted p577
A sound game plan can help you roll with the punches in uncertain times.
Mari Paul
doi:10.1038/nbt0609-577
http://links.ealert.nature.com/ctt?kn=41&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
PEOPLE
People p578
doi:10.1038/nbt0609-578
http://links.ealert.nature.com/ctt?kn=50&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Interested in finding out more about biotechnology research in Mainland China and Hong Kong?
Every week, the Editors of Nature China survey the scientific literature to identify the best recently published papers from Mainland China and Hong Kong and provide a summary of the results.
Take a look at the recent biotechnology highlights:
http://links.ealert.nature.com/ctt?kn=81&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=14&m=33418469&r=MTc3MTg2NzE2NgS2&b=2&j=NTE0Njk2MTYS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
